Trontinemab
Trontinemab is an investigational anti-amyloid antibody in Phase 3. It is not approved and is not for self-administration.
Overview
Roche’s Brainshuttle programme aims to improve brain uptake. Phase 3 safety and benefit are still being established. A trial listing is not a recommendation to join a study.
Investigational amyloid-directed antibody designed for enhanced brain delivery (Brainshuttle). Connects to Amyloid-beta.
1.Trontinemab binds Amyloid-beta.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Trontinemab" OR ABSTRACT:"Trontinemab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Trontinemab, not a curated reading list.
Similar pages
not linked directly; found by shared links- PathwayAmyloid and tau cascade (simplified)
Shares Amyloid-beta, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyBlood Alzheimer biomarkers
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentSemaglutide (EVOKE programme)
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentDonanemab
Shares Amyloid-beta, Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentRemternetug
Shares Amyloid-beta, Alzheimer’s disease and the tag dementia-atlas.
- IdeaBlood test before PET or lumbar puncture
Shares Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.
- TermMild cognitive impairment
Shares Mild cognitive impairment and the tag dementia-atlas.
- TreatmentLecanemab
Shares Amyloid-beta, Mild cognitive impairment, Alzheimer’s disease and the tag dementia-atlas.